secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0000950170-24-043417
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus enters amended employment agreements with CEO and CFO; base salaries $622,804 and $463,455
--------------------------------------------------------------------------------

- CEO Yuval Cohen's 2-year agreement: base salary $622,804, bonus target up to 60% of base.
- CFO Sean Moran's 2-year agreement: base salary $463,455, bonus target up to 40% of base.
- Change-in-control severance: CEO 24 months salary, CFO 18 months; plus accelerated equity vesting.
- Non-compete (6 months) and non-solicitation (12 months) apply, conditional on severance.
- Agreements expire April 10, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024043417/0000950170-24-043417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024043417/crbp-20240409.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-043417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer